Chromocell Therapeutics (CHRO) Stock Price, News & Analysis

Company Overview

Chromocell Therapeutics is a clinical-stage biotechnology company focused on the development of autologous cell therapies for the treatment of peripheral nerve injury and degenerative neuropathies. Headquartered in Greater Boston, the company leverages proprietary technologies to isolate, expand and reinfuse patient-derived supportive cells, aiming to repair damaged nerves and restore function. Chromocell’s mission centers on addressing conditions for which there are currently limited or no effective therapeutic options, including chronic compressive lesions and diabetic neuropathy.

At the core of Chromocell’s pipeline is the OmniChrom™ cell manufacturing platform, designed to produce highly purified Schwann cell products with consistent potency and safety profiles. The lead clinical candidate, CHRO-101, is an autologous Schwann cell therapy being evaluated in Phase 1/2 trials for patients suffering from carpal tunnel syndrome and other compressive neuropathies. In parallel, preclinical programs seek to extend the platform’s potential to sensory and motor nerve injuries, leveraging transitional state Schwann cells to enhance nerve regeneration in both peripheral and, eventually, central nervous system indications.

Founded in 2018 as a spin-out from leading academic research institutions, Chromocell has since built a multidisciplinary team of experts in cell biology, neurology and scalable manufacturing. The company’s operations span the United States and Europe, working collaboratively with clinical sites and regulatory agencies to advance its cell therapy candidates. Under the guidance of a management team with decades of experience in biotech development and clinical translation, Chromocell Therapeutics aims to establish a new standard for regenerative medicine in neurodegenerative and nerve injury disorders.

Key Stats

• Today's Range: $1.23 to $1.48
• 50-Day Range: $1.34 to $13.50
• 52-Week Range: $4.50 to $38.00
• Volume: 194,032 shs
• Average Volume: 46,073 shs
• Market Capitalization: $8.69 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CHRO Stock Analysis - Frequently Asked Questions

How have CHRO shares performed this year?

Chromocell Therapeutics' stock was trading at $6.41 at the beginning of 2025. Since then, CHRO stock has decreased by 79.1% and is now trading at $1.34.

When did Chromocell Therapeutics' stock split?

Shares of Chromocell Therapeutics reverse split on Wednesday, July 2nd 2025.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, July 1st 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Chromocell Therapeutics IPO?

Chromocell Therapeutics (CHRO) raised $7 million in an initial public offering (IPO) on Friday, February 16th 2024. The company issued 1,100,000 shares at $6.00 per share.

How do I buy shares of Chromocell Therapeutics?

Shares of CHRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 7/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:CHRO
• Previous Symbol: NYSE:CHRO
• CIK: 1919246
• Web: chromocell.com
• Phone: 732-514-2636
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.24)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.38 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -453.90%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.60
• Quick Ratio: 0.60

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.65) per share
• Price / Book: -0.81

Miscellaneous

• Outstanding Shares: 6,485,000
• Free Float: 5,039,000
• Market Cap: $8.69 million
• Optionable: N/A
• Beta: 3.63